Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunmax Biotechnology CoROCO:4728 +1.06%91 EBITDA Margin % is 48.04% as of Dec. 2025, which is 14% above its 10-year median of 41.97. GuruFocus rates ROCO:4728 with a GF Score™ of 91/100 and a GF Value™ of NT$441.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Sunmax Biotechnology Co ranks better than 95.1% on this metric.
Sunmax Biotechnology Co (ROCO:4728) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sunmax Biotechnology Co EBITDA Margin % Related Terms
Sunmax Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4728 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Sunmax Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunmax Biotechnology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunmax Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sunmax Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunmax Biotechnology Co (ROCO:4728) has a EBITDA Margin % of 48.04% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunmax Biotechnology Co and its competitors. This is 14% above median its historical median of 41.97. Over the past decade, Sunmax Biotechnology Co's EBITDA Margin % has ranged from 8.27 to 108.14. According to the industry distribution chart, Sunmax Biotechnology Co ranks #46 out of 939 companies in the Biotechnology industry, placing it in the top 4.9%.
Is Sunmax Biotechnology Co's EBITDA Margin % too high?
Sunmax Biotechnology Co's current EBITDA Margin % of 48.04% is 14% above median its 10-year median of 41.97. Over the past 10 years, this metric has ranged from a low of 8.27 to a high of 108.14. Based on the distribution chart, Sunmax Biotechnology Co ranks #46 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunmax Biotechnology Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunmax Biotechnology Co ranks #46 out of 939 companies for EBITDA Margin %. This places Sunmax Biotechnology Co in the top 5% of its industry — outperforming the majority of peers. Historically, Sunmax Biotechnology Co's own EBITDA Margin % has ranged from 8.27 to 108.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunmax Biotechnology Co and its competitors. Sunmax Biotechnology Co's current EBITDA Margin % is 48.04%, which is 14% above median its own 10-year median of 41.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$441.22, compared to a current price of NT$381.00 — trading 13.6% below its estimated fair value. The current EBITDA Margin % is 48.04%, which is 14% above median its 10-year median of 41.97. Sunmax Biotechnology Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current EBITDA Margin % is 48.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?
Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be undervalued.
The current stock price of NT$381.00 is trading 13.6% below its estimated GF Value™ of NT$441.22.
GuruFocus considers Sunmax Biotechnology Co to be Modestly Undervalued.
Key valuation signals for ROCO:4728:
EBITDA Margin %: 48.04% (14% above median its 10-year median of 41.97)
GF Value™: NT$441.22 vs. price of NT$381.00 (13.6% below fair value)
No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
91GF Score
Get the complete analysis for ROCO:4728
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4728 has been successfully added to your 
